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A B S T R A C T
Purpose: Data from animal models has nicely shown that inﬂammatory processes in the central nervous
system (CNS) can modulate seizure frequency. However, a potential relationship between the
modulation of seizure frequency and gene expression of key inﬂammatory factors in human epileptic
tissue is still unresolved. Brain tissue from pharmacoresistant patients with mesial temporal lobe
epilepsy (mTLE) provides a unique prerequisite for clinico-neuropathological correlations. Here, we have
concentrated on gene expression of the human key inﬂammatory mediators, TLR4, ATF-3 and IL8, in
correlation to seizure frequency and additional clinical parameters in human epileptic brain tissue of
pharmacoresistant mTLE patients. Furthermore, we characterized the cell types expressing the
respective proteins in epileptic hippocampi.
Methods: Total RNAs were isolated from n = 26 hippocampi of pharmacoresistant mTLE patients using
AllPrep DNA/RNA Mini Kit. cRNA was used for hybridization on Human HT-12 v3 Expression BeadChips
with Illumina Direct Hybridization Assay Kit and resulting gene expression data was normalized based
on the Illumina BeadStudio software suite by means of quantile normalization with background
subtraction. Corresponding human hippocampal sections for immunohistochemistry were probed with
antibodies against TLR4, ATF-3, IL8 and glial ﬁbrillary acidic protein (GFAP), neuronal nuclear protein
(NeuN) and the microglial marker HLA-DR.
Results: We observed abundant TLR4 gene expression to relate to seizure frequency per month. For ATF-
3, we found an inverse correlation of expression to seizure frequency. Lower expression of IL8 was
signiﬁcantly associated with high seizure frequency. Further, we detected TLR4 expression in neurons
and GFAP-positive astrocytes of pharmacoresistant mTLE patients. Only neurons of human epileptic
hippocampi express ATF-3. IL8 was expressed in microglia and reactive astrocytes.
Conclusion: Our results suggest a differential correlation of key inﬂammatory factor expression in
epileptic hippocampi and seizure frequency in patients. The modulation of such processes may open new
therapeutic perspectives for treating seizures.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Brain injuries such as neurotrauma, febrile seizures, infections
or status epilepticus induce inﬂammatory responses and this in* Corresponding author at: Department of Neuropathology, University of Bonn
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http://dx.doi.org/10.1016/j.seizure.2013.04.023turn can be associated with acute symptomatic seizures and a high
risk of developing chronic epilepsy.1,2 In human patients only little is
known about differential expression of inﬂammatory factors in
correlation to seizure frequency and other clinical parameters. In
this context, we have focused on the key human inﬂammatory
mediators, toll-like receptor 4 (TLR4), ATF-3 and IL8, for the following
reasons: TLR4 has previously been shown as key trigger of
inﬂammation by inducing the gene transcription of several
cytokines and contribute to seizure formation and severity in a
TLE animal model.3 In kainate-induced epileptic mice and invier Ltd. All rights reserved.
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in pyramidal neurons and GFAP-positive astrocytes.3 A negative
regulator of TLR4,4 the immediate early and adaptive response gene
ATF-3 modulates the expression of genes critically involved in
inﬂammatory responses.5 ATF-3 expression is dynamically altered
by the exposure of cells to many stimuli including epileptic activity
in the brain.6 IL8, as one of the ﬁrst chemokines identiﬁed in the
human brain, is known to be expressed exclusively in humans but
not in rodents. Previous data suggest expression of IL8 particularly in
microglia and astrocytes7 and an association of intrathecal IL8
synthesis and seizure frequency has been reported.8 Furthermore,
ATF-3 impacts the expression of chemokines.9 Here, we have used
our unique access to human epileptic brain tissue from epilepsy
surgery in order to investigate the role of these key mediators of
inﬂammatory processes in correlation to seizure frequency.
2. Materials and methods
We used human bioptic brain tissue to analyze the gene
expression data in correlation to the seizure frequency from
patients (n = 26) with chronic pharmacoresistant mTLE,10 who
underwent surgical treatment in the Epilepsy Surgery Program at
the University of Bonn Medical Center. The patient group under
study (n = 26 Caucasians) is particularly well characterized with
respect to seizure documentation and represents substantial
differences in seizure frequency (Supplemental Table 1). In all
patients, presurgical evaluation using a combination of non-
invasive and invasive procedures revealed that seizures originated
in the mesial temporal lobe.11 Surgical resection of the hippocam-
pus was clinically indicated due to pharmacoresistance in every
case and all procedures were conducted in accordance with the
Declaration of Helsinki and approved by the ethics committee of
the University of Bonn Medical Center. Informed written consent
was obtained from all patients. Based on screening the Center’sFig. 1. Relative gene expression of TLR4, ATF-3 and IL8 in correlation to seizure frequency. (
patients with pharmacoresistant mTLE (r = 0.408; *p = 0.02; n = 24). (B) Low ATF-3 expres
(r = 0.431; *p = 0.01; n = 26). (C) Relative expression data revealed a signiﬁcant correlat
n = 23). Different n-numbers for the individual genes are due to the fact that expressiofresh frozen hippocampal tissue bank by fresh frozen sections and
hematoxylin & eosin staining, care was taken to provide tissue
samples representing all hippocampal subﬁelds from the corpus
hippocampi for every case included in the present study. Whereas
the majority of hippocampi revealed the pattern of Ammon’s horn
sclerosis (AHS; segmental neuronal cell loss and concomitant
astrogliosis and microglia activation), the other hippocampi in the
present series lacked the characteristic segmental neuronal cell
loss but showed astrogliosis and microglia activation. Those were
associated with lesions such as cortical dysplasia or epilepsy-
associated tumors. Diagnosis according to international criteria
was established by an experienced neuropathologist (AJB) in every
case.12,13 In the course of establishing a nucleic acid bank of
respective specimens, genomic DNA and total RNA were isolated
from hippocampal tissue samples using AllPrep DNA/RNA Mini Kit
(Qiagen, Hilden) according to manufacturer’s protocol. For the
following analyses, we used only the respective RNA. A total
amount of 750 ng cRNA was used for hybridization on Human HT-
12 v3 Expression BeadChips with Illumina Direct Hybridization
Assay Kit (Illumina, San Diego, CA). The data we extracted for genes
of interest was previously analyzed using Illumina’s GenomeStu-
dio Gene Expression Module. Gene expression data were normal-
ized using the Illumina BeadStudio software suite by means of
quantile normalization with background subtraction. Expression
values that were ‘‘not detectable’’ for individual genes, were
omitted from the further analysis. Human hippocampal parafﬁn
slices were stained with antibodies against TLR4 (1:20; Santa Cruz
Biotechnology, Heidelberg; sc-10741), ATF-3 (1:500; Santa Cruz
Biotechnology, Heidelberg; sc-22798), IL8 (1:200; Santa Cruz
Biotechnology, Heidelberg; sc-7922) and Glial ﬁbrillary acidic
Protein (GFAP) (1:350; Sigma–Aldrich, Munich, Germany; G3893),
neuronal nuclear protein (NeuN) (1:500; Millipore, Billerica, MA
USA; MAB377) and HLA-DR (1:1000; Dako, Hamburg, Germany;
M0746). Correlation analyses between gene expression levels inA) Abundant TLR4 expression signiﬁcantly correlated with high seizure frequency in
sion levels are signiﬁcantly associated with high seizure frequency in mTLE patients
ion of low IL8 expression and high seizure frequency (r = 0.675; ***p = 1.7  1004;
n values that were ‘‘not detectable’’ had to be omitted from the analysis.
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the Pearson product moment correlation (r) and the correlation t-
test (p) using the statistical language R.
3. Results and discussion
We investigated the expression and distribution of the key
inﬂammatory mediators TLR4, ATF-3 and IL8 in human hippocam-
pal tissue and a potential correlation of seizure frequency and
expression of respective genes. We observed that abundant TLR4
expression correlated signiﬁcantly with high seizure frequency
(Pearson correlation coefﬁcient: r = 0.407; two-tailed t-test:
p = 0.047; n = 24; Fig. 1A). For ATF-3 we found that patients with
high seizure frequency show low levels of gene expression
(r = 0.431; two-tailed t-test: p = 0.027; n = 26; Fig. 1B). The
minor ATF-3 expression and abundant TLR4 expression in patients
with high seizure frequency may support the role of ATF-3 as a
negative regulator of TLR4 signaling in human epileptic hippo-
campi.4 Furthermore, ATF-3 has been suggested as a regulator of
chemokine expression.9 Low expression of the human speciﬁc IL8
chemokine is signiﬁcantly correlated with high seizure frequency
(r = 0.671; two-tailed t-test: p = 1.7  1004; n = 23; Fig. 1C).
Intriguingly, in our present analyses the human-speciﬁcFig. 2. Immunohistochemical analyses of TLR4, ATF-3 and IL8 in human hippocampal ti
antibody showed that TLR4 (red) is localized in neurons and reactive astrocytes in mTL
expressed in both, neurons and reactive astrocytes (scale bar = 50 mm). (B1) ATF-3 (red) i
3 (red) is strongly expressed in representative neurons (scale bar = 50 mm). (C1) Co-imm
protein GFAP (green) showed that IL8 (red) is expressed in microglia and reactive astrocyt
in microglia and reactive astrocytes (scale bar = 50 mm). (For interpretation of the refer
article.)inﬂammatory mediator IL8 showed the most signiﬁcant correla-
tion of gene expression and seizure frequency in human epileptic
brain tissue. Particularly, these data may underline the need for
analyses in human epileptic tissue complementary to animal
models, where these analyses for obvious reasons are not possible.
In order to address co-correlation of the reported associations of
gene expression levels with other clinical parameters, we carried
out a comprehensive co-variance analysis of clinical and thera-
peutic data of the patients included here (Supplemental Table 2).
These analyses did not result in signiﬁcant associations of TLR4,
ATF-3 and IL8 mRNA expression with any of the additional
individual parameters investigated. Complementarily, we exam-
ined potential inter-correlations among the three inﬂammatory
mediator expression levels based on the seizure frequency. To this
end, we performed a one-way MANOVA to test for comprehensive
expression dynamics of the inﬂammatory mediators under study.
One-way MANOVA revealed a signiﬁcant multivariate main effect
in the expression of inﬂammatory mediators based on seizure
frequency (Pillai’s trace statistic = 2.281, F(45, 27) = 1.905,
p = 0.039). Power to detect the effect was 0.943 (Supplemental
Table 3).
Recent studies in hippocampal tissue of pharmacoresistant
mTLE patients with hippocampal sclerosis indicated TLR4ssue. (A1) Co-immunoreactions against NeuN and GFAP (both green, as indicated)
E patients (scale bar = 100 mm). (A2) In higher magniﬁcation, TLR4 (red signal) is
s localized in neurons (NeuN, green; scale bar = 100 mm) in mTLE patients. (B2) ATF-
unohistochemistry against the microglial protein HLA-DR (green) and the astrocytic
es (scale bar = 100 mm). (C2) Higher magniﬁcation conﬁrms the presence of IL8 (red)
ences to color in this ﬁgure legend, the reader is referred to the web version of this
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We found consistent expression patterns in pharmacoresistant
mTLE patients by immunohistochemical reactions with antibodies
against GFAP and NeuN (Fig. 2A). We did not observe TLR4
expression in microglia (data not shown). The presence of TLR4 in
neurons and reactive astrocytes in human epileptic tissue and the
increased expression in patients with high seizure frequency may
underline a potential modifying role of TLR4 for seizure frequency
in human epilepsy. Previous data suggested expression of ATF-3 in
nuclei of dentate gyrus granule cells after kainate induced
epilepsy.14 Glial cells as well as reactive astrocytes lacked ATF-3
expression.15 By double immunoﬂuorescence, we here observed
ATF-3 expression in neurons expressing NeuN in parafﬁn sections
of human hippocampal tissue (NeuN, Fig. 2B). Expression of ATF-3
protein was neither detected in glial components such as reactive
astrocytes (data not shown) nor in microglia components (data not
shown). In contrast, the chemokine IL8 has been described to be
produced exclusively by microglial cells and astrocytes.7 We
performed double-immunoﬂuorescence analyses using antibodies
directed against HLA-DR and GFAP to investigate the expression of
IL8 in human hippocampal brain tissue. We found IL8 as expressed
in both, microglia and reactive astrocytes (Fig. 2C). However, IL8
revealed no co-expression with the neuronal marker NeuN (data
not shown).
Our results suggest a substantial correlation between gene
expression of inﬂammatory key mediators and seizure frequency
in epileptic patients. Considering the fact that factors under study
are differentially expressed in pharmacoresistant mTLE hippo-
campi, pharmacological interference with such cascades may
provide new vistas of anticonvulsive therapy in the future.
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